Company Name Roche

Industry Biotechnology, Pharmaceuticals, Diagnostics

Company F. Hoffmann-La Roche AG

Founded 1896
29 Roche medicines on the WHO Essential Medicines List
91, 747 employees with geographical presence in over 100 countries
Ranked most sustainable healthcare company in the Dow Jones Sustainability Indices for
the eight year
Roche Products (India) Private Limited (formerly known as Roche Scientific Company Pvt.
Ltd.) was incorporated in 1994 as a wholly owned subsidiary of Roche Group.
In November 2010, the companys name was changed to "Roche Products (India) Pvt. Ltd
Tagline We innovate healthcare
About Roche is a Swiss multinational biotech company with differentiated medicines in oncology,
immunology, infectious diseases, ophthalmology and diseases of the central nervous
system.
Roche is also one of the top companies in vitro diagnostics (medical devices) and tissue-
based cancer diagnostics as well as diabetes management.
According to Pharm Execs, Roche ranks at 3 in Top 50 pharmaceutical companies 2017
Division Pharmaceuticals Diagnostics
In India, key focus areas for Roche are Oncology, Transplantation, Anaemia and
Rheumatoid Arthritis
Domicile Basel, Switzerland
Competitors Johnson & Johnson, Pfizer, Novartis, Merck & Co, Amgen etc.
Key People Christoph Franz Chairman
Dr Severin Schwan CEO Roche Group
Daniel Oday (CEO Pharmaceuticals)
Roland Diggelmann (CEO Diagnostics)
Financials Revenue: CHF 50,576 million (2016) +4% increase
Sales in pharmaceutical division CHF 39.1 billion (3% increase)
Sales in Diagnostic division CHF 11.5 billion (7% increase)
PAT: CHF 9,576 million (2016)
Subsidiaries Chugai Pharmaceutical, Japan
through M&A Ventana
Genentech, US In 2009, Roche acquired a US-based biotechnology company
Genentech to strengthen its portfolio in personalized healthcare

Segments:
Pharmaceuticals
o Roche Pharmaceuticals
o Chugai
Diagnostics
o Professional Diagnostics
o Molecular Segments
o Tissue Diagnostics
o Diabetes Care
Recent Products & Solutions

Four new medicines were launched to treat aggressive cancersskin cancer (Cotellic), lung
cancer (Alecensa; Tecentriq), leukaemia (Venclexta) and bladder cancer (Tecentriq)
Five medicines have been granted breakthrough therapy designation by the US Food and Drug
Administration (It allows the FDA to grant priority review to drug candidates if
preliminary clinical trials indicate that the therapy may offer substantial treatment
advantages over existing options for patients with serious or life-threatening diseases)
During 2016, Roche added nine key diagnostic instruments to its portfolio
New immunochemistry platform cobas e 801 was launched that can carry up to 300
immunological tests per hour to enable doctors to make faster treatment decisions
74 new molecular entities (NMEs) are in the research pipeline at different stages of clinical
trials

News:

In January 2017, the company acquired ForSight Labs and digital diabetes management
platform, mySugr
In November 2016, the company launched the global cancer immunotherapy Centers of
Research Excellence (imCORE) Network which will bring together world's leading scientific and
clinical experts in cancer immunotherapy to collaborate in investigating the most promising new
treatment approaches
In January 2016, the company announced it would acquire Tensha Therapeutics for $115 million
upfront, with $420 million in contingent payments.